ResMed Study Finds CPAP Adherence Improved by Remote Monitoring, Self-Monitoring across 3 Countries
May 21 2019 - 9:00AM
Business Wire
- Study presented at ATS International
Conference examined more than 4 million PAP users in U.S., Brazil,
Mexico
Remote monitoring and patient self-monitoring can drive CPAP
adherence for people with sleep apnea, according to research
presented by ResMed (NYSE: RMD) (ASX: RMD) at the American Thoracic
Society’s 2019 ATS International Conference.
Average adherence to PAP (positive airway pressure), the gold
standard for treating sleep apnea, is approximately 50 percent when
using legacy technology with no cloud connectivity or remote
monitoring capabilities. According to the new study, researchers
found significantly higher rates when they evaluated patients on
100% cloud-connectable devices that enable remote monitoring: more
than 31,000 Brazilians, 17,000 Mexicans, and 4.1 million
Americans.
Percent of study
participants achieving 90-day PAP adherence (all Remotely and
remotely monitored) self-monitored United
States 74% 85% Brazil 72% 83% Mexico
66% 81%
“These results equate a strong endorsement for remote and
self-monitoring technology,” said study coauthor and ResMed Chief
Medical Officer Carlos M. Nunez, M.D. “Despite different healthcare
systems, financial and social issues, patients in all three
countries have reached above-average adherence rates when treated
with 100% cloud-connectable PAP devices.”
Researchers also urge clinicians to enroll their PAP patients in
a self-monitoring program like myAir, ResMed’s patient engagement
app. While 26 percent of U.S. patients in this study had registered
for myAir, only 8.1 percent of Brazilian patients and 2.8 percent
of Mexican patients had.
PAP adherence was defined for this study using the U.S. Centers
for Medicare and Medicaid Services definition: using PAP usage of
four hours per night for 70 percent of nights in a 30-day span
within the first 90 days of therapy.
About ResMed
At ResMed (NYSE: RMD) (ASX: RMD) we pioneer innovative solutions
that treat and keep people out of the hospital, empowering them to
live healthier, higher-quality lives. Our cloud-connected medical
devices transform care for people with sleep apnea, COPD and other
chronic diseases. Our comprehensive out-of-hospital software
platforms support the professionals and caregivers who help people
stay healthy in the home or care setting of their choice. By
enabling better care, we improve quality of life, reduce the impact
of chronic disease and lower costs for consumers and healthcare
systems in more than 120 countries. To learn more, visit
ResMed.com and follow @ResMed.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190521005262/en/
For mediaJayme Rubenstein+1
858.836.6798news@resmed.com
For investorsAmy Wakeham+1
858.836.5000investorrelations@resmed.com
Resmed (ASX:RMD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Resmed (ASX:RMD)
Historical Stock Chart
From Apr 2023 to Apr 2024